Your shopping cart is currently empty

SRI-42127 is a novel small molecule inhibitor of the RNA regulatory factor HuR, which inhibits tumor growth, attenuates glial activation in a lipopolysaccharide-induced neuroinflammation model, and reduces neuropathic pain after nerve injury by inhibiting the neuroinflammatory response.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $58 | - | In Stock | |
| 5 mg | $139 | - | In Stock | |
| 10 mg | $255 | - | In Stock | |
| 25 mg | $513 | - | In Stock | |
| 50 mg | $728 | - | In Stock | |
| 100 mg | $985 | - | In Stock | |
| 500 mg | $1,970 | - | In Stock |
| Description | SRI-42127 is a novel small molecule inhibitor of the RNA regulatory factor HuR, which inhibits tumor growth, attenuates glial activation in a lipopolysaccharide-induced neuroinflammation model, and reduces neuropathic pain after nerve injury by inhibiting the neuroinflammatory response. |
| In vitro | SRI-42127 (0.05-1 μM; 24 h) inhibits HuR translocation in LPS-activated glial cells in vitro, significantly reducing the production of pro-inflammatory mediators such as IL1β, IL-6, TNF-α, iNOS, CXCL1, and CCL2[1]. |
| In vivo | SRI-42127 (15 mg/kg; intraperitoneal injection; single dose) inhibits in vivo microglial activation and reduces neutrophil and monocyte recruitment/chemotaxis[1]. |
| Molecular Weight | 348.4 |
| Formula | C19H20N6O |
| Cas No. | 2727872-68-4 |
| Smiles | N1=CC=2C=CC(=CC2N1)C3=CN=C4C=CC(=NN43)N(C)C5CCOCC5 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (86.11 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (5.74 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.